Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas-Reference-Cited by-同舟云学术

Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas

Published:2021-03-02 Issue:3 Volume:39 Page:336-348
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Dimou Maria¹^ORCID,Papageorgiou Sotirios G.²^ORCID,Stavroyianni Niki³,Katodritou Eirini⁴,Tsirogianni Maria⁵,Kalpadakis Christina⁶,Banti Anastasia⁷,Arapaki Maria⁸,Iliakis Theodoros¹,Bouzani Maria⁹,Verrou Eugenia⁴,Spanoudakis Emmanouil¹⁰,Giannouli Stavroula¹¹,Marinakis Theodoros¹²,Mandala Evdokia¹³,Mparmparousi Despoina¹⁴,Sachanas Sotirios¹⁵,Dalekou‐Tsolakou Maria¹⁶,Hatzimichael Eleftheria¹⁷,Vadikolia Chryssa¹⁸,Violaki Vasiliki¹⁹,Poziopoulos Christos²⁰,Tsirkinidis Pantelis²¹,Chatzileontiadou Sofia²²,Vervessou Elissavet²³,Ximeri Maria⁶,Sioni Anastasia⁵,Konstantinidou Pavlina⁴,Kyrtsonis Marie‐Christine¹,Siakantaris Marina P.⁸,Angelopoulou Maria K.⁸^ORCID,Pappa Vassiliki²^ORCID,Konstantopoulos Kostas⁸,Panayiotidis Panayiotis¹,Vassilakopoulos Theodoros P.⁸^ORCID

Affiliation:

1. First Department of Internal Medicine, Propaedeutic, Haematology Clinical Trial Unit Laikon General Hospital, National and Kapodistrian University of Athens Athens Greece

2. Second Department of Internal Medicine, Propaedeutic, Hematology Unit University General Hospital “Attikon”, National and Kapodistrian University of Athens Athens Greece

3. Department of Hematology Papanikolaou Hospital Thessaloniki Greece

4. Department of Hematology Theagenion Cancer Hospital Thessaloniki Greece

5. Department of Hematology Aghios Savvas Anticancer Hospital Athens Greece

6. Department of Hematology University of Crete Iraklion Crete Greece

7. Hematology Department Papageorgiou Hospital Thessaloniki Greece

8. Department of Haematology and Bone Marrow Transplantation Laikon General Hospital, National and Kapodistrian University of Athens Athens Greece

9. Department of Hematology and Lymphoma Evangelismos General Hospital Athens Greece

10. Department of Hematology Democritus University of Trace Alexandroupolis Greece

11. Second Department of Internal Medicine Ippokrateion General Hospital Athens Greece

12. Department of Clinical Hematology “G. Gennimatas” General Hospital Athens Greece

13. Forth Department of Medicine Faculty of Medicine Aristotle University of Thessaloniki Hippokration Hospital Thessaloniki Greece

14. Department of Therapeutics National and Kapodistrian University of Athens Alexandra Hospital Athens Greece

15. Department of Hematology Athens Medical Center Athens Greece

16. General Hospital of Kalamata Kalamata Greece

17. Department of Hematology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece

18. Department of Hematology 424 Army Hospital Thessaloniki Greece

19. Department of Hematology Chania General Hospital Chania Greece

20. Department of Hematology Metropolitan Hospital N. Faliron Athens Greece

21. Department of Hematology 401 Army Hospital Athens Greece

22. Hematology Unit 1st Department of Internal Medicine Aristotle University of Thessaloniki AHEPA Hospital Thessaloniki Greece

23. Department of Hematology Henry Dynant Hospital Athens Greece

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2842

Reference42 articles.

1. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

3. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

4. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

2. Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications;Current Issues in Molecular Biology;2024-07-05

3. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-25

4. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin;Expert Opinion on Drug Safety;2024-05-02

5. Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project;eJHaem;2024-02-23